{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:55:50Z","timestamp":1784307350865,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The issue of unblinded outcome-assessors and patients has repeatedly been stressed as a flaw in allegedly double-blind antidepressant trials. Unblinding bias can for example result from a drug\u2018s marked side effects. If such unblinding bias is present for a given drug, then it might be expected that the placebos of that drug are rated significantly less effective than that of other antidepressants.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>To test this hypothesis, the present exploratory analysis conducted a Bayesian network meta-analysis (NMA) comparing the efficacy of 19 different placebos in placebo-controlled trials provided in the dataset by Cipriani et al. (Lancet 2018; 391: 1357\u201366). Primary outcome was efficacy (continuous) estimated on the standardized mean difference (SMD) scale and defined as the pre-post change\u00a0on the Hamilton Depression scale (HAMD-17), on which information was available in <jats:italic>N<\/jats:italic>\u00a0=\u2009258 trials.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Comparative placebo ranking suggested mirtazapine-placebo (SMD -2.0 [\u2212\u20095.0\u20131.0 95% CrI]) to be the most, and amitriptyline- (SMD 1.2 [\u2212\u20091.6\u20133.9 95% CrI]) and trazodone- (SMD 2.1 [\u2212\u20090.9\u20135.2 95% CrI]) placebos to be the least effective placebos. Other placebos suggested to be more effective than amitriptyline- and trazodone-placebos (based on 95% CrIs excluding zero) were citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, and venlafaxine placebos. These NMA results were corroborated by the observation that the relative efficacy between drug and placebo was considerably larger for amitriptyline and trazodone than for instance mirtazapine, duloxetine, and venlafaxine, supported by a small and insignificant correlation between drug-efficacy and placebo-efficacy (r\u2009=\u2009\u2212\u20090.202, <jats:italic>p<\/jats:italic>\u00a0=\u20090.408).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The present exploratory NMA indicates that distinguishable side effects of older drugs may unblind outcome-assessors thus resulting in overestimation of the average drug-placebo difference and underrating bias in placebo-arms, particularly for the older antidepressant drugs amitriptyline and trazodone. If confirmed in prospective studies, these findings suggest that efficacy rankings for antidepressants are susceptible to bias and should be considered unreliable or misleading. The analysis is limited by the focus on the single-comparison placebos (76%, i.e., placebos assessed in two-arm trials), since double-comparison placebos (25%, i.e., placebos assessed in three-arm trials) are hard to interpret and therefore not included in the present interpretation. Another limitation is the problem of multiplicity, which was only approximately accounted for in the Bayesian NMA by modelling treatment effects as exchangeable.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12888-020-02839-y","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T12:02:41Z","timestamp":1599480161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-3649","authenticated-orcid":false,"given":"Lisa","family":"Holper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Hengartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"issue":"6","key":"2839_CR1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024886","volume":"9","author":"K Munkholm","year":"2019","unstructured":"Munkholm K, Paludan-M\u00fcller AS, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ Open. 2019;9(6):e024886.","journal-title":"BMJ Open"},{"issue":"10128","key":"2839_CR2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366.","journal-title":"Lancet"},{"key":"2839_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.11.012","volume":"18","author":"L Holper","year":"2020","unstructured":"Holper L. Optimal doses of antidepressants in dependence on age: combined covariate actions in Bayesian network meta-analysis. EClinicalMedicine. 2020;18:100219.","journal-title":"EClinicalMedicine."},{"issue":"2","key":"2839_CR4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229381","volume":"15","author":"MP Hengartner","year":"2020","unstructured":"Hengartner MP, Jakobsen JC, S\u00f8rensen A, Pl\u00f6derl M. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg depression rating scale, the gold standard clinician rating scale: a meta-analysis of randomised placebo-controlled trials. PLoS One. 2020;15(2):e0229381.","journal-title":"PLoS One"},{"issue":"7","key":"2839_CR5","doi-asserted-by":"crossref","first-page":"e0159267-e","DOI":"10.1371\/journal.pone.0159267","volume":"11","author":"MJ Page","year":"2016","unstructured":"Page MJ, Higgins JPT, Clayton G, Sterne JAC, Hr\u00f3bjartsson A, Savovi\u0107 J. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. PLoS One. 2016;11(7):e0159267-e.","journal-title":"PLoS One"},{"issue":"5","key":"2839_CR6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","volume":"187","author":"J Savovic","year":"2018","unstructured":"Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. Am J Epidemiol. 2018;187(5):1113\u201322.","journal-title":"Am J Epidemiol"},{"key":"2839_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000012304","volume":"68","author":"D Antonuccio","year":"1999","unstructured":"Antonuccio D, Danton W, DeNelsky G, Greenberg R, Gordon J. Raising questions about antidepressants. Psychother Psychosom. 1999;68:3\u201314.","journal-title":"Psychother Psychosom"},{"issue":"6","key":"2839_CR8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005053-199306000-00002","volume":"181","author":"S Fisher","year":"1993","unstructured":"Fisher S, Greenberg RP. How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis. 1993;181(6):345\u201350.","journal-title":"J Nerv Ment Dis"},{"issue":"1572","key":"2839_CR9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1098\/rstb.2010.0394","volume":"366","author":"MS Mora","year":"2011","unstructured":"Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1879\u201388.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"3","key":"2839_CR10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000346144","volume":"82","author":"C Baethge","year":"2013","unstructured":"Baethge C, Assall OP, Baldessarini RJ. Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000-2010. Psychother Psychosom. 2013;82(3):152\u201360.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"2839_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1192\/bjp.177.1.47","volume":"177","author":"C Even","year":"2000","unstructured":"Even C, Siobud-Dorocant E, Dardennes RM. Critical approach to antidepressant trials: blindness protection is necessary, feasible and measurable. Br J Psychiatry. 2000;177(1):47\u201351.","journal-title":"Br J Psychiatry"},{"issue":"7526","key":"2839_CR12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(67)90635-6","volume":"290","author":"P Leyburn","year":"1967","unstructured":"Leyburn P. A critical look at antidepressant drug trials. Lancet. 1967;290(7526):1135\u20138.","journal-title":"Lancet"},{"issue":"5","key":"2839_CR13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1037\/0022-006X.60.5.664","volume":"60","author":"RP Greenberg","year":"1992","unstructured":"Greenberg RP, Bornstein RF, Greenberg MD, Fisher S. A meta-analysis of antidepressant outcome under \"blinder\" conditions. J Consult Clin Psychol. 1992;60(5):664\u20139.","journal-title":"J Consult Clin Psychol"},{"issue":"7","key":"2839_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041778","volume":"7","author":"A Khan","year":"2012","unstructured":"Khan A, Faucett J, Lichtenberg P, Kirsch I, Brown WA. A systematic review of comparative efficacy of treatments and controls for depression. PLoS One. 2012;7(7):e41778.","journal-title":"PLoS One"},{"key":"2839_CR15","doi-asserted-by":"crossref","unstructured":"Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev. 2004;1:CD003012.","DOI":"10.1002\/14651858.CD003012.pub2"},{"issue":"12","key":"2839_CR16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","volume":"26","author":"A Fagiolini","year":"2012","unstructured":"Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033\u201349.","journal-title":"CNS Drugs"},{"issue":"4","key":"2839_CR17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00002512-199404040-00006","volume":"4","author":"M Haria","year":"1994","unstructured":"Haria M, Fitton A, McTavish D. Trazodone. Drugs Aging. 1994;4(4):331\u201355.","journal-title":"Drugs Aging"},{"issue":"S403","key":"2839_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0447.2000.tb10944.x","volume":"101","author":"S Peretti","year":"2000","unstructured":"Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand. 2000;101(S403):17\u201325.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2839_CR19","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-230","volume":"11","author":"F Naudet","year":"2013","unstructured":"Naudet F, Millet B, Charlier P, Reymann JM, Maria AS, Falissard B. Which placebo to cure depression? A thought-provoking network meta-analysis. BMC Med. 2013;11(1):230.","journal-title":"BMC Med"},{"issue":"11","key":"2839_CR20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","volume":"3","author":"TA Furukawa","year":"2016","unstructured":"Furukawa TA, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016;3(11):1059\u201366.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"2839_CR21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2839_CR22","volume-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"S Dias","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trialsNational Institute for health and care excellence (NICE); 2011."},{"key":"2839_CR23","volume-title":"JAGS version 4.3.0 user manual","author":"M Plummer","year":"2017","unstructured":"Plummer M. JAGS version 4.3.0 user manual; 2017."},{"key":"2839_CR24","volume-title":"WinBUGS user manual","author":"D Spiegelhalter","year":"2003","unstructured":"Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS user manual; 2003."},{"issue":"4","key":"2839_CR25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodology. 2002;64(4):583\u2013639.","journal-title":"J R Stat Soc Series B Stat Methodology"},{"issue":"1","key":"2839_CR26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jrsm.1377","volume":"11","author":"O Efthimiou","year":"2020","unstructured":"Efthimiou O, White IR. The dark side of the force: multiplicity issues in network meta-analysis and how to address them. Res Synth Methods. 2020;11(1):105\u201322.","journal-title":"Res Synth Methods"},{"issue":"4","key":"2839_CR27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jrsm.1256","volume":"8","author":"A B\u00e9liveau","year":"2017","unstructured":"B\u00e9liveau A, Goring S, Platt RW, Gustafson P. Network meta-analysis of disconnected networks: how dangerous are random baseline treatment effects? Res Synth Methods. 2017;8(4):465\u201374.","journal-title":"Res Synth Methods"},{"key":"2839_CR28","volume-title":"NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment","author":"S Dias","year":"2012","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustmentNational Institute for health and care excellence (NICE); 2012."},{"key":"2839_CR29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","volume":"72","author":"N Khin","year":"2011","unstructured":"Khin N, Chen Y-F, Yang Y, Yang P, Laughren T. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011;72:464\u201372.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2839_CR30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","volume":"37","author":"J Undurraga","year":"2012","unstructured":"Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37(4):851\u201364.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"2839_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2009.01.029","volume":"118","author":"W Rief","year":"2009","unstructured":"Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1):1\u20138.","journal-title":"J Affect Disord"},{"issue":"14","key":"2839_CR32","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","volume":"287","author":"BT Walsh","year":"2002","unstructured":"Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major DepressionVariable, substantial, and growing. JAMA. 2002;287(14):1840\u20137.","journal-title":"JAMA."},{"issue":"1","key":"2839_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/eb-2017-102827","volume":"21","author":"TA Furukawa","year":"2018","unstructured":"Furukawa TA, Cipriani A, Leucht S, Atkinson LZ, Ogawa Y, Takeshima N, et al. Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. Evid Based Ment Health. 2018;21(1):1.","journal-title":"Evid Based Ment Health"},{"key":"2839_CR34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199512004-00004","volume":"10","author":"T de Boer","year":"1995","unstructured":"de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10:19\u201323.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"2839_CR35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00002018-199717040-00005","volume":"17","author":"S Kasper","year":"1997","unstructured":"Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf. 1997;17(4):251\u201364.","journal-title":"Drug Saf"},{"issue":"3","key":"2839_CR36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2005-864120","volume":"38","author":"K Grasm\u00e4der","year":"2005","unstructured":"Grasm\u00e4der K, PLV K-UK, Frahnert C, Hiemke C, Dragicevic A, von Widdern O, et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry. 2005;38(3):113\u20137.","journal-title":"Pharmacopsychiatry."},{"issue":"3","key":"2839_CR37","first-page":"215","volume":"24","author":"CR Dolder","year":"2012","unstructured":"Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry. 2012;24(3):215\u201324.","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"2839_CR38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/PL00004913","volume":"355","author":"N Haddjeri","year":"1996","unstructured":"Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the \u03b12-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch Pharmacol. 1996;355(1):20\u20139.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"2839_CR39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249\u201364.","journal-title":"CNS Drug Rev"},{"issue":"5","key":"2839_CR40","first-page":"PCC.13r01525","volume":"15","author":"A Alam","year":"2013","unstructured":"Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013;15(5):PCC.13r01525.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"3","key":"2839_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0165-0327(98)00224-9","volume":"51","author":"J Fawcett","year":"1998","unstructured":"Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51(3):267\u201385.","journal-title":"J Affect Disord"},{"issue":"5","key":"2839_CR42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","volume":"85","author":"AF Carvalho","year":"2016","unstructured":"Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270\u201388.","journal-title":"Psychother Psychosom"},{"key":"2839_CR43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajp.2014.12.002","volume":"13","author":"JA Chen","year":"2015","unstructured":"Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJH, Cusin C, et al. Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum depression trial study group. Asian J Psychiatr. 2015;13:23\u20139.","journal-title":"Asian J Psychiatr"},{"issue":"9","key":"2839_CR44","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.mayocp.2015.06.016","volume":"90","author":"M Zimmerman","year":"2015","unstructured":"Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Have treatment studies of depression become Even less generalizable? A review of the inclusion and exclusion criteria used in placebo-controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015;90(9):1180\u20136.","journal-title":"Mayo Clin Proc"},{"key":"2839_CR45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.04.009","volume":"124","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Egger M, Salanti G. In network meta-analysis, most of the information comes from indirect evidence: empirical study. J Clin Epidemiol. 2020;124:42\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2839_CR46","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1409-3","volume":"17","author":"C Palpacuer","year":"2019","unstructured":"Palpacuer C, Hammas K, Duprez R, Laviolle B, Ioannidis JPA, Naudet F. Vibration of effects from diverse inclusion\/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis. BMC Med. 2019;17(1):174.","journal-title":"BMC Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02839-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T23:28:47Z","timestamp":1630970927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02839-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2839"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02839-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"18 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}